Concurrent weekly docetaxel chemotherapy in combination with radiotherapy for stage III and IVA-B nasopharyngeal carcinoma

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 3, 2012, Pages 785-789

  Wei, Wei Hong ^a   Cai, Xiu Yu ^a   Xu, Tao ^a   Zhang, Guo Yi ^a   Wu, Yong Feng ^a   Feng, Wei Neng ^a,b   Lin, Li ^a   Deng, Yan Ming ^a,b   Lu, Qiu Xia ^a   Huang, Zhe Li ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b THE FIRST PEOPLE S HOSPITAL OF FOSHAN   (China)

Author keywords

Chemoradiotherapy; Cisplatin; Docetaxel; Nasopharyngeal carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOCETAXEL; TAXOID;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER STAGING; CHEMORADIOTHERAPY; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; FEMALE; FOLLOW UP; HUMAN; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NASOPHARYNX CARCINOMA; NASOPHARYNX TUMOR; RADIATION DOSE; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; CHEMORADIOTHERAPY; CISPLATIN; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NEOPLASM STAGING; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES; TAXOIDS; YOUNG ADULT;

EID: 84871695003     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.3.785     Document Type: Article

References (23)

1. Al-Sarraf M, LeBlanc M, Giri PG, et al (1998). Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol, 16, 1310-7.
2. Baujat B, Audry H, Bourhis J, et al (2006). Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized trials and 1753 patients. Int J Radiat Oncol Biol Phys, 1, 47-56.
3. Biete Solà A, Marruecos Querol J, Calvo Manuel FA, et al (2007). Phase II trial, concurrent radio-chemotherapy with weekly docetaxel for advanced squamous cell carcinoma of head and neck. Clin Transl Oncol, 9, 244-50.
4. Chan AT, Leung SF, Ngan RK, et al (2005). Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst, 97, 536-9.
5. Cao SM, Simons MJ, Qian CN (2011). The prevalence and prevention of nasopharyngeal carcinoma in China. Chin J Cancer, 30,114-9.
6. Calais G, Bardet E, Sire C, et al (2004). Radiotherapy with concomitant weekly docetaxel for Stages III/IV oropharynx carcinoma. Results of the 98-02 GORTEC Phase II trial. Int J Radiat Oncol Biol Phys, 58, 161-6.
7. Chen M, Wu SX, Chen YY, et al (2004). Radiation therapy concurrent with weekly paclitaxel for locoregionally advanced nasopharyngeal carcinoma: outcomes of a phase I trial. Am J Clin Oncol, 27, 481-4.
8. Chen CY, Lu TX, Zhao C, et al (2007). Weekly paclitaxel with concurrent intensity-modulated radiotherapy for nasopharyngeal carcinoma: outcomes of a tolerance trial. Ai Zheng, 26, 398-402.
9. Fukada J, Shigematsu N, Takeda A, et al (2010). Weekly low-dose docetaxel-based chemoradiotherapy for locally advanced oropharyngeal or hypopharyngeal carcinoma: a retrospective, single-institution study. Int J Radiat Oncol Biol Phys, 76, 417-24.
10. Hui EP, Ma BB, Leung SF, et al (2009). Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma. J Clin Oncol, 27, 242-9.
11. Hu W, Ding W, Yang H, et al (2009). Weekly paclitaxel with concurrent radiotherapy followed by adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma. Radiother Oncol, 93, 488-91.
12. Lin JC, Jan JS, Hsu CY, et al (2003). Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. J Clin Oncol, 21, 631-7.
13. Langendijk JA, Leemans CR, Buter J, et al (2004). The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma: a meta-analysis of the published literature. J Clin Oncol, 22, 4604-12.
14. Lee AW, Lau WH, Tung SY, et al (2005). Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group. J Clin Oncol, 23, 6966-75.
15. Lai SZ, Li WF, Chen L, et al (2011). How does intensity-modulated radiotherapy versus conventional two-dimensional radiotherapy influence the treatment results in nasopharyngeal carcinoma patients? Int J Radiat Oncol Biol Phys, 80, 661-8.
16. Posner MR, Hershock DM, Blajman CR, et al (2007). Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med, 357, 1705-15.
17. Tishler RB, Geard CR, Hall EJ, et al (1992). Taxol sensitizes human astrocytoma cells to radiation. Cancer Res, 52, 3495-7.
18. Tishler RB, Schiff PB, Geard CR, et al (1992). Taxol: a novel radiation sensitizer. Int J Radiat Oncol Biol Phys, 22, 613-7.
19. Tishler RB, Norris CM, Colevas AD, et al (2002). A phase I/II trial of concurrent docetaxel and radiation after induction chemotherapy in patients with poor prognosis squamous cell carcinoma of the head and neck. Cancer, 95, 1472-81.
20. Tishler RB, Posner MR, Norris CM Jr, et al (2006). Concurrent weekly docetaxel and concomitant boost radiation therapy in the treatment of locally advanced squamous cell cancer of the head and neck. Int J Radiat Oncol Biol Phys, 65, 1036-44.
21. Vermorken JB, Remenar E, van Herpen C, et al (2007). Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med, 357, 1695-704.
22. Wahl AF, Donaldson KL, Fairchild C, et al (1996). Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nat Med, 2, 72-9.
23. Wee J, Tan EH, Tai BC, et al (2005). Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety. J Clin Oncol, 23, 6730-8.